Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
Home > Products > Novel inhibitors

Oxatomide

  Cat. No.:  DC40317   Featured
Chemical Structure
60607-34-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 60607-34-3
Chemical Name: Oxatomide
Synonyms: 1-(3-(4-Benzhydrylpiperazin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one;1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one;Oxatomide;3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one;Celtect;KW-4354;Oxatimide;Oxatomida;Oxatomidum;Oxatomidum [INN-Latin];Oxetal;Tinset;HY-123205;A832804;NCGC00015774-04;NCGC00094235-02;KS-1375;CBMicro_024634;1{-[4-(diphenylmethyl)-1-piperzinyl]propyl}-1,3-dihydro-2H-benzimidazol-2-one;OXATOMIDE [WHO-DD];R 35,443;3-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1H-benzimidazol-2-one;OXATOMIDE [MART.];Tox21_110219_1;REGID_for_CID_4615;NS00004457;EU-0100924;60607-34-3;Dasten;oxatomide;EN300-25890425;EINECS 262-320-9;FT-0630723;1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one;CHEMBL13828;BIM-0024581.P001;DB12877;SCHEMBL28824;F97990;SR-01000076051;Lopac0_000924;cid_4615;W-105243;OXATOMIDE [JAN];3-[3-[4-(diphenylmethyl)piperazin-1-yl]propyl]-1H-benzimidazol-2-one;HMS2089N07;J31IL9Z2EE;1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone;CCG-11811;NSC-771641;NCGC00015774-01;AB04841;UNII-J31IL9Z2EE;Oxatomide [USAN:INN:BAN:JAN];D01773;OXATOMIDE [INN];SMR000058301;1-{3-[4-(diphenylmethyl)-1-piperazinyl}-propyl}-1,3-dihydro-2H-benzimidazol-2-one;AKOS000507212;2H-Benzimidazol-2-one, 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-;R-35443;1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone;BRN 4724760;MFCD00211147;O 9387;Q2071515;CHEBI:31943;CS-0081837;OXATOMIDE [MI];Oxatomida [INN-Spanish];2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-;McN-JR 35443;Celtect (TN);Oxatomide, >=99%;NSC309710;3-[3-(4-benzhydrylpiperazino)propyl]-1H-benzimidazol-2-one;NSC-309710;NCGC00015774-05;HMS3372K08;NCGC00015774-06;C27H30N4O;MLS000028549;DTXSID4045181;Oxatomide (JAN/USAN/INN);Oprea1_338592;AB01227629-02;NSC771641;CAS-60607-34-3;Lopac-O-9387;1-(3-(4-Benzhydrylpiperazin-1-yl)propyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one;BDBM76863;NCGC00015774-03;NCGC00094235-01;R 35443;NSC 309710;SR-01000076051-1;1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one;HMS2231H12;OXATOMIDE [USAN];NCGC00015774-02;DTXCID2025181;Tox21_110219;Cobiona;1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1,3-dihydro-2H-benzimidazol-2-one
SMILES: C1=CC=C(C=C1)C(C2=CC=CC=C2)N3CCN(CCCN4C5=CC=CC=C5N=C4O)CC3
Formula: C27H30N4O
M.Wt: 426.5533
Purity: >98%
Sotrage: Please store the product under the recommended conditions in the Certificate of Analysis.
MSDS
TITLE DOWNLOAD
MSDS_23330_DC40317_60607-34-3
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC72335 JNJ10191584 JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively.
DC71335 Norastemizole Tecastemizole (Norastemizole), a major metabolite of Astemizole, is a potent and selective H1 receptor antagonist. Tecastemizole shows anti-inflammatory activities.
DC47622 Cyclizine Cyclizine is a piperazine first-generation antagonist of histamine 1 receptor.
DC41225 Dimaprit dihydrochloride Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits nNOS with an IC50 of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion.
DC40317 Oxatomide Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin.
DC28113 Imetit dihydrobromide Imetit dihydrobromide (VUF 8325 dihydrobromide) is a high affinity and potent agonist of histamine H3 and H4 receptors, with Ki values of 0.3 and 2.7 nM, respectively. Imetit mimics histamine effect in triggering a shape change in eosinophils (EC50=25 nM).
DC12166 JNJ-5207852 JNJ-5207852 is a selective and potent histamine H3 receptor (H3R) antagonist, with pKis of 8.9, 9.24 for rat and human H3R, respectively.
DC9467 Epinastine Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.
DC9466 Ciproxifan (maleate) Ciproxifan maleate(FUB-359 maleate) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.
DC9896 Cinnarizine Cinnarizine is a medication derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia